OneAscent Financial Services LLC Purchases New Position in Health Catalyst, Inc. (NASDAQ:HCAT)

OneAscent Financial Services LLC acquired a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 13,754 shares of the company’s stock, valued at approximately $97,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of HCAT. Point72 Asset Management L.P. lifted its position in Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after acquiring an additional 211,805 shares in the last quarter. Impax Asset Management Group plc grew its stake in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after acquiring an additional 195,525 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after acquiring an additional 66,896 shares during the last quarter. State Street Corp lifted its stake in shares of Health Catalyst by 2.5% in the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after acquiring an additional 28,251 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Health Catalyst in the fourth quarter valued at about $110,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on HCAT. Stifel Nicolaus dropped their price objective on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a report on Thursday, February 27th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a report on Wednesday, January 8th. Wells Fargo & Company reduced their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Piper Sandler dropped their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. Finally, Citigroup reduced their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.27.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $4.01 on Friday. The company has a market cap of $281.55 million, a P/E ratio of -2.97 and a beta of 1.43. The business has a 50 day moving average of $4.89 and a two-hundred day moving average of $6.73. Health Catalyst, Inc. has a 52 week low of $3.72 and a 52 week high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Insider Activity at Health Catalyst

In other news, insider Linda Llewelyn sold 6,442 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total transaction of $37,363.60. Following the completion of the transaction, the insider now owns 92,260 shares of the company’s stock, valued at approximately $535,108. The trade was a 6.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the sale, the general counsel now directly owns 160,437 shares in the company, valued at approximately $729,988.35. This trade represents a 7.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,530 shares of company stock worth $299,572 in the last 90 days. 2.50% of the stock is currently owned by company insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.